Lite Strategy, Inc. annual report, FY2019

Filing identity and reporting period

Material metadata mismatch: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2020—not a Lite Strategy, Inc. filing or a 2018 Q4 report. The summary below reflects the filing text provided.

Business context

MEI Pharma is a clinical-stage oncology company with four drug candidates: zandelisib, voruciclib, ME-344 and pracinostat. It has not commercialized a drug; reported revenue is from collaboration and license arrangements, primarily with Kyowa Kirin (KKC) and Helsinn.

Financial results and liquidity

Amounts below are in millions of dollars unless stated otherwise.

FY2020 revenue rose mainly because of KKC licensing and collaboration activity. The net loss includes a $22.9 million non-cash warrant-liability expense; the comparable FY2019 result included $27.6 million of non-cash warrant-liability income. These fair-value changes substantially affect reported net loss and are not operating cash flows. The filing reports no interest-bearing debt; total liabilities were $131.5 million, including $82.5 million of deferred revenue and a $40.5 million warrant liability.

Cash from operations included substantial advance payments and deferred revenue. The company also disclosed $45.3 million of operating cash used when excluding the $79.6 million KKC license fee received during the year. A further $20.4 million of the KKC upfront payment was withheld by Japanese tax authorities and recorded as a receivable; MEI expected recovery in FY2021. Management said resources were expected to fund operations into FY2022 and beyond; the financial-statement note separately states they were sufficient for at least 12 months from issuance.

In the June 2020 quarter, revenue was $25.5 million and net loss was $18.5 million, compared with FY2019’s June quarter revenue of $1.1 million and net income of $3.1 million. The filing attributes large quarterly net-income swings in part to warrant-liability remeasurement.

Material changes and notable developments

• In April 2020, MEI entered a global zandelisib agreement with KKC. KKC paid $100 million upfront; $20.4 million was withheld in Japan. MEI and KKC share U.S. development costs and profits 50/50, with MEI recording U.S. sales revenue. KKC leads and generally funds development and commercialization outside the U.S. MEI may receive up to approximately $582.5 million in milestones plus tiered ex-U.S. royalties.
• MEI completed a December 2019 equity offering and FY2020 at-the-market sales, raising net proceeds of $48.5 million and $20.7 million, respectively. Shares outstanding increased to 111.5 million at June 30, 2020 from 73.5 million a year earlier. Potential dilution also includes 16.1 million warrants and 11.3 million options outstanding at year-end.
• Research and development expense rose to $34.1 million from $32.3 million, with increased zandelisib trial activity and personnel costs. General and administrative expense increased to $16.7 million from $14.6 million.

Outlook, risks and contingencies

• Zandelisib: The TIDAL Phase 2 trial is intended to support an FDA accelerated-approval application. Enrollment continued at a reduced rate during COVID-19; completion was projected for calendar Q1 2021. Updated Phase 1b data showed an 83% overall response rate in 36 evaluable follicular-lymphoma patients; the median duration of response had not been reached. These are clinical-trial results, not evidence of approval or established commercial efficacy.
• Pracinostat: Helsinn discontinued the Phase 3 AML study in July 2020 after an interim futility analysis indicated it was unlikely to meet the overall-survival endpoint. Further development, including MDS, was under review. MEI recorded a $0.2 million impairment of related intangible assets. The filing reports a putative securities class action filed August 10, 2020 alleging misleading pracinostat statements; MEI disputes the claims, and the outcome was not predictable.
• COVID-19: The pandemic had negatively affected clinical-development timelines and could further disrupt enrollment, trial sites, vendors, manufacturing, data collection and regulatory review. MEI reported no material expected CARES Act impact.
• Funding and development: MEI expects operating losses and negative operating cash flow for the foreseeable future, and anticipates R&D expense to rise. It may need additional equity, licensing or partnership financing; future financing is not assured and equity issuance may dilute shareholders.
• Other obligations: The new San Diego office lease runs from July 2020 through March 2028, with approximately $11.5 million of total contractual payments. Potential milestone and royalty obligations include up to $179 million under the Presage agreement for voruciclib and up to $75.2 million under the S*Bio agreement for pracinostat, subject to specified milestones and sales.

Key facts investors should verify

• Confirm the intended issuer and period: the provided document is MEI Pharma’s FY2020 10-K, not the company and 2018 Q4 period in the request.
• Track TIDAL enrollment, timing, final efficacy and safety data, and whether FDA agrees with the proposed accelerated-approval pathway.
• Check collection of the $20.4 million Japanese tax-withholding receivable and the timing and recognition of KKC-related deferred revenue.
• Assess cash burn and runway against management’s FY2022 outlook, planned R&D spending and potential financing needs.
• Monitor the pracinostat MDS program, the securities litigation, and the impact of the halted AML trial on further development and collaboration.
• Review dilution from shares already issued, outstanding warrants and options, and any future capital raises.